Alert detail
FDA Approval: DEGEVMA (DENOSUMAB-ADET) — Type 5 - New Formulation or New Manufacturer
Policy ID: FDA-BLA761481Specialty: OncologyAdded: 10/2/2026Effective: September 25, 2026billing update
What changed
Denosumab biosimilar DEGEVMA approved; watch for new J-code assignment.
Who’s affected: Oncology billing teams · Effective: September 25, 2026
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.